Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies

Allergy, Asthma & Clinical Immunology

RESEARCH  

OPEN ACCESS

• Paul RatnerEmail author,
• Charles P. Andrews,
• Frank C. Hampel,
• Bruce Martin,
• Dale E. Mohar,
• Denis Bourrelly,
• Parisa Danaietash,
• Sara Mangialaio,
• Jasper Dingemanse,
• Abdel Hmissi and
• Jay van Bavel

Allergy, Asthma & Clinical Immunology201713:18

DOI: 10.1186/s13223-017-0183-z

Abstract

Background

Antagonism of chemoattractant receptor-homologous molecule on T-helper type-2 cells (CRTH2), a G-protein coupled receptor for prostaglandin D2, could be beneficial for treating allergic disorders. We present findings on the efficacy and safety/tolerability of a CRTH2 antagonist (setipiprant) in participants with seasonal allergic rhinitis (AR) in a real-life setting over 2 weeks.

Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study

Clinical and Molecular Allergy

RESEARCH

 

OPEN ACCESS

• I. Djuric-Filipovic,
• Marco CaminatiEmail author,
• D. Filipovic,
• C. Salvottini and
• Z. Zivkovic

Clinical and Molecular Allergy201715:7

DOI: 10.1186/s12948-017-0064-5

Abstract

Background

Allergen-specific immunotherapy (AIT) is the only treatment able to change the natural course of allergic diseases. We aimed at investigating the clinical efficacy of SLITOR (Serbian registered vaccine for sublingual allergen specific immunotherapy).

The 2016 classification criteria for primary Sjogren’s syndrome: what’s new

BMC Medicine

COMMENTARY

OPEN ACCESS

• Franco Franceschini,
• Ilaria CavazzanaEmail author,
• Laura Andreoli and
• Angela Tincani

BMC Medicine201715:69

DOI: 10.1186/s12916-017-0837-1

Abstract

New 2016 ACR/EULAR classification criteria for primary Sjogren’s syndrome (SS) have been developed and endorsed by the ACR. The newly proposed criteria include simple-to-perform items.

Vitamin D deficiency and interleukin-17 relationship in severe obstructive sleep apnea–hypopnea syndrome

ORIGINAL ARTICLE

Year : 2017  |  Volume : 12  |  Issue : 2  |  Page : 107-113

Sonia Toujani1, Wajih Kaabachi2, Meriem Mjid1, Kamel Hamzaoui2, Jouda Cherif1, Majed Beji1 1 Department of Basic Sciences, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia 2 Unit Research 12SP15 “Homeostasis and Cell Dysfunction”, Abderrahman Mami Hospital, Ariana, Tunisia Correspondence Address: Sonia Toujani Department of Basic Sciences, Faculty of Medicine of Tunis, University of Tunis El Manar Tunisia Check DOI: 10.4103/atm.ATM_301_16

Abstract   Purpose: We aimed to assess Vitamin D (VD) abnormalities in patients with severe obstructive sleep apnea–hypopnea syndrome (OSAHS), to study its association with clinical and polygraphic data, and to correlate VD levels with interleukin-17 (IL-17). Methods: Ninety-two patients with severe OSAHS were consecutively enrolled between September 2014 and February 2016 and compared to age-, sex-, and body mass index (BMI)-matched controls. Anthropometric parameters and medical history were collected. The serum levels of VD and IL-17 were determined by radioimmunoassay and enzyme-linked immunosorbent assay, respectively.

Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study

Vaccine

Available online 5 April 2017

In Press, Corrected Proof — Note to users

Jolanta Airey^a, , , 

Frank R. Albano^a, 

Daphne C. Sawlwin^b, 

Alison Graves Jones^b, 

Neil Formica^a, 

Vince Matassa^a, 

Jane Leong^c

  Open Access

---

Highlights

•

First report of Seqirus IIV4 in children aged 5–17 years.

•

Immunogenicity of Seqirus IIV4 was noninferior to a US-licensed comparator IIV4.

•

Fever rates were similar for both vaccines in children 5–8 years and 9–17 years.

---

Abstract

Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study

Research

BMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1415

Cite this as: BMJ 2017;357:j1415

Akbar K Waljee, assistant professor1 2 3 4, Mary A M Rogers, research associate professor2 4 5, Paul Lin, statistican2,Amit G Singal, associate professor6, Joshua D Stein, associate professor2 7 8, Rory M Marks, associate professor 9,John Z Ayanian, professor2 5 8, Brahmajee K Nallamothu, professor 1 2 4 10
Author affiliations
Correspondence to: A K Waljee awaljee@med.umich.edu
Abstract
Objective To determine the frequency of prescriptions for short term use of oral corticosteroids, and adverse events (sepsis, venous thromboembolism, fractures) associated with their use.

Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma

ORIGINAL RESEARCH

          

• Abstract
• Fulltext
• Metrics
• Get Permission

Sy Duong-Quy,^1–3 Thuc Vu-Minh,⁴ Thong Hua-Huy,¹ Tram Tang-Thi-Thao,³ Khiet Le-Quang,³ Dinh Tran-Thanh,³ Nhu Doan-Thi-Quynh,³ Nhat-Nam Le-Dong,⁵ Timothy J Craig,² Anh-Tuan Dinh-Xuan<sup>1

1</sup>Department of Respiratory Physiology, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cité, Paris, France; ²Department of Medicine, Penn State University, Hershey, PA, USA; ³Bio-Medical Research Center, Lam Dong Medical College, Dalat, ⁴Department of Immuno-Allergology, ENT National Institute, Hanoi, Vietnam; ⁵Department of Pulmonology, St Elisabeth Hospital, Namur, Belgium

Background: The measure of fractional exhaled nitric oxide (FENO) in the airways is a useful tool to guide the diagnosis and titration of inhaled corticosteroids in patients with asthma. However, its role in diagnosis of allergic rhinitis (AR), especially in subjects with asthma, is not well established.
Objective: To study the cutoff of nasal FENO in the diagnosis of subjects with AR and AR-asthma compared to age-matched subjects without AR or asthma and its correlations with the clinical and functional characteristics.

Japanese guidelines for allergic diseases 2017

Editorial

Japanese guidelines for allergic diseases 2017
Ken Ohta, Kenji Izuhara
p161–162
Published in issue: April 2017
Full-Text HTMLPDF

Invited Review Articles

Review Series: Japanese Guidelines for Allergic Diseases 2017

Japanese guidelines for adult asthma 2017
Masakazu Ichinose, Hisatoshi Sugiura, Hiroyuki Nagase, Masao Yamaguchi, Hiromasa Inoue, Hironori Sagara, Jun Tamaoki, Yuji Tohda, Mitsuru Munakata, Kohei Yamauchi, Ken Ohta, The Japanese Society of Allergology
p163–189
Published online: February 11, 2017
Full-Text HTMLPDF